儿童核心结合因子相关急性髓细胞白血病的细胞分子遗传学异常与预后

Prognostic significance of cellular and molecular genetic abnormalities in pediatric core binding factor-acute myeloid leukemia

核心结合因子相关急性髓细胞白血病(CBF-AML)是儿童急性髓细胞白血病(AML)的常见细胞遗传学亚型,占AML的25%~30%,临床预后较好。但是,仍有30%~40% CBF-AML患者发生复发,而该类患者伴随的细胞分子遗传学异常事件可能与其临床预后相关。目前已有达沙替尼应用于成年人CBF-AML的报道,因此不同分子遗传学背景亦成为精准靶向治疗的新思路,但是儿童CBF-AML的相关研究仍较少。笔者通过对儿童CBF-AML中常见的细胞分子遗传学异常与其对临床预后的影响进行综述,旨在为儿童CBF-AML的个体化治疗提供新的思路。

Core binding factor-acute myeloid leukemia (CBF-AML) is a common cellular genetic subtype in children with acute myeloid leukemia (AML), accounting for 25%-30% of AML, and it has a good clinical prognosis. However, there are still 30%-40% of CBF-AML patients with recurrence, and the cellular molecular genetic abnormal events accompanying such patients may be related to their clinical prognosis. At present, dasatinib has been reported in the therapy of adult CBF-AML. Different molecular genetic backgrounds have become a new idea for precise targeted therapy, but there are still few related studies on pediatric CBF-AML. The author summarizes clinical prognostic impacts of cellular and molecular genetic abnormalities which are commonly seen in pediatric CBF-AML, aiming to provide new ideas for individualized treatment of pediatric CBF-AML.